3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Melanoma
3
Recurrence
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Glioma
1
Ependymoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Rituximab
66
Cyclophosphamide
52
fludarabine phosphate
26
fludarabine
22
Filgrastim
21
Vincristine
19
Methotrexate
19
Melphalan
19
Doxorubicin
18
Radiotherapy
17
Etoposide
17
Prednisone
16
Tacrolimus
15
Whole-Body Irradiation
14
Mycophenolic Acid
14
Cytarabine
14
Peripheral Blood Stem Cell Transplantation
13
Gemcitabine
13
Cyclosporine
13
Antilymphocyte Serum
13
Lenalidomide
12
Busulfan
11
Bortezomib
11
Granulocyte Colony-Stimulating Factor
9
Alemtuzumab
9
sargramostim
8
Dexamethasone
8
Cord Blood Stem Cell Transplantation
8
pembrolizumab
7
ibritumomab tiuxetan
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts